Does ARK Invest in BNGO: The Bottom Line. At this time, ARK does not invest in BNGO. With that said, the company does appear to have some promise in its own right. Like all speculative small-cap companies, Bionano Genomics is a risky stock to own.
Similarly, Is BNGO a meme stock?
Admittedly, it has been a while since Bionano Genomics (NASDAQ:BNGO) stock has been a “hot stock,” a “meme stock” or whatever you want to call it. Since its big drop in late February and early March, the market has had mixed feelings about this life sciences company.
Who owns Bionano genomics? Top 10 Owners of Bionano Genomics Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 5.74% | 16,609,007 |
| The Vanguard Group, Inc. | 4.86% | 14,064,639 |
| SSgA Funds Management, Inc. | 2.49% | 7,198,880 |
| Geode Capital Management LLC | 1.63% | 4,714,883 |
Thereof, What does Bionano genomics do?
Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents.
Is Bionano stock a buy?
Bionano Genomics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
What does Bionano genomics do Reddit?
Without going into the science which won’t mean much to most of us – it’s a company that runs human genome mapping at scale, and allows doctors to detect genetic variants which can lead to new cancer treatments, and a bunch of other cool stuff that reads like science fiction, but is become more and more a reality.
Is BNGO an American company?
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. … The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
What sector is BNGO in?
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space.
What institutions are buying NIO?
Largest shareholders include Baillie Gifford & Co, BlackRock Inc., Vanguard Group Inc, State Street Corp, VWIGX – Vanguard International Growth Fund Investor Shares, Susquehanna International Group, Llp, Goldman Sachs Group Inc, Citadel Advisors Llc, VEIEX – Vanguard Emerging Markets Stock Index Fund Investor Shares, …
Where is BNGO based?
The company was founded in 2003 and is headquartered in San Diego, California.
Where is BNGO located?
The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
How does BioNano genomics make money?
Revenue is produced by either directly selling the data to outsiders or by leveraging it for internal reasons, such as increasing the efficacy of advertising.
Is BNGO a strong buy?
According to the issued ratings of 3 analysts in the last year, the consensus rating for Bionano Genomics stock is Buy based on the current 3 buy ratings for BNGO.
Who are BNGO competitors?
The main competitors of Bionano Genomics include Olink Holding AB (publ) (OLK), Cytek BioSciences (CTKB), Cue Health (HLTH), Quanterix (QTRX), Singular Genomics Systems (OMIC), Berkeley Lights (BLI), Nautilus Biotechnology (NAUT), Akoya Biosciences (AKYA), EyePoint Pharmaceuticals (EYPT), and Rapid Micro Biosystems ( …
What does BioNano genomics do?
Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents.
What is Saphyr?
The Saphyr is BioNano’s third generation optical mapping solution and delivers rapid, high throughput, long range genome mapping with structural variation detection capabilities critical for genome research.
How many shares does BNGO have?
BioNano Genomics Inc (US:BNGO) has 292 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 83,218,166 shares.
Who are BioNano genomics competitors?
13 Competitors
BioNano Genomics’s competitors are BioDiscovery, Fluxion Biosciences, IRX Therapeutics, Hepregen, Genvault Corporation and more.
Is BNGO in any ETFs?
ETF.com Insight
Bionano Genomics, Inc. is a company in the U.S. stock market and it is a holding in 30 U.S.-traded ETFs. BNGO has around 17.2M shares in the U.S. ETF market. The largest ETF holder of BNGO is the iShares Russell 2000 ETF (IWM), with approximately 6.72M shares.
What companies invested BNGO?
Bionano Genomics (NASDAQ:BNGO) Institutional Buying and Selling
| Reporting Date | Hedge Fund | Ownership in Company |
|---|---|---|
| 2/11/2022 | Geode Capital Management LLC | 1.630% |
| 2/11/2022 | Charles Schwab Investment Management Inc. | 0.709% |
| 2/11/2022 | Bank of Montreal Can | 0.082% |
| 2/10/2022 | JPMorgan Chase & Co. | 0.064% |
Join TheMoney.co community and don’t forget to share this post !
